Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

Fig. 2

PFS with advanced HER2-positive breast cancer on immune related protein. Positive CD8, CFRhigh group and negative PDL1 group had significantly longer PFS than negative CD8, CFRlow group and positive PDL1 group, respectively: a (p = 0.045, log-rank), c (p = 0.007, log-rank), e (p = 0.040, log-rank). Other immune related protein expression were not related to PFS: b FOXP3, d PD1, f CD163, g PTEN, h LAG3

Back to article page